Acta medica Austriaca最新文献

{"title":"ESC Congress 2003 – European Society of Cardiology","authors":"","doi":"10.1046/j.1563-2571.2003.03003_2.x","DOIUrl":"https://doi.org/10.1046/j.1563-2571.2003.03003_2.x","url":null,"abstract":"","PeriodicalId":6945,"journal":{"name":"Acta medica Austriaca","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1046/j.1563-2571.2003.03003_2.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137787696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EANM ’03 – Annual Congress of the European Association of Nuclear Medicine","authors":"","doi":"10.1046/j.1563-2571.2003.03001_2.x","DOIUrl":"https://doi.org/10.1046/j.1563-2571.2003.03001_2.x","url":null,"abstract":"","PeriodicalId":6945,"journal":{"name":"Acta medica Austriaca","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1046/j.1563-2571.2003.03001_2.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137787697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Stellungnahme zum Marktrückzug von Cerivastatin","authors":"J. R. Patsch","doi":"10.1046/j.1563-2571.2002.02002.x","DOIUrl":"https://doi.org/10.1046/j.1563-2571.2002.02002.x","url":null,"abstract":"","PeriodicalId":6945,"journal":{"name":"Acta medica Austriaca","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1046/j.1563-2571.2002.02002.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72151618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapie der endokrinen Orbitopathie mit Somatostatin-Analoga bei Patienten mit positivem Octreo-Scan","authors":"R. Pichler,&nbsp;W. Maschek,&nbsp;C. Holzinger","doi":"10.1046/j.1563-2571.2001.01024.x","DOIUrl":"10.1046/j.1563-2571.2001.01024.x","url":null,"abstract":"<p><b>Zusammenfassung:</b> Wir untersuchten prospektiv 28 Personen mit aktiver endokriner Orbitopathie und positivem Sonographiebefund (A-mode) der extraokulären Augenmuskel. Zur Beurteilung des Somatostatin-Rezeptor-Status wurden SPECT-Aufnahmen der Orbitae mit einer Doppelkopf-Gammakamera nach der Applikation von 110 MBq 111-In-Pentreotide durch­geführt. 9 Patienten (beziehungsweise 12/56 Bulbi) zeigten einen deutlich erhöhten Uptake (Faktor &gt; 2 in zirkulären ROIs bei semiquantitativer Auswertung) und wurden für eine Therapie mit Lanreotide (30 mg i. m. alle 14 Tage) selektiert. Aufgrund klinischer Progression wurde bei 5 Personen eine Kontrollszintigraphie durchgeführt, die bei zwei von ihnen ein positives Ergebnis zeigte. Mit Ausnahme eines Patienten wurden milde Nebenerscheinungen der Lanreotidetherapie (Diarrhoe) toleriert. Nach Erreichen der fibrotischen Phase an den bulbären Muskeln in 3 – 10 Monaten wurde die Medikation abgesetzt. Diese Untergruppe (außer zwei Frauen, denen in Folge zusätzlich Kortikosteroide verabreicht wurden) präsentierte einen stabilen Krankheitsverlauf. Eine der beiden musste jedoch wegen drohender Atrophie des N. opticus akut einer operativen Sanierung zugeführt werden. Klinische augenfachärztliche Kontrollen zeigten bei den Patienten, die frühzeitig Somatostatin-Analoga erhielten – so ein positiver Octreo-Scan-Befund vorlag – viel versprechende Ergebnisse.</p><p>Therapy with Somatostatin Analogs in Patients with Graves’ Ophthalmopathy and Positive Octreoscan</p><p><b>Summary:</b> We prospectively evaluated 28 persons with active endocrine ophthalmopathy and positive sonographic criteria (A-mode) on extraocular eye muscles. To evaluate somatostatin-­receptor status SPECT of the orbits was perfor­med with a double-headed rotating gamma camera after application of 110 MBq 111-In-Pentreotide. 9 patients (12/56 eyes respectively) showed a marked uptake ratio (&gt; 2 in circular ROIs by semiquantitative calculation) and were selected for lanreotide (30 mg i. m. every 14 d) treatment. 5 individuals had control scan after clinical progression which became positive in two of them. All but one tolerated modest side-effects of lanreotide treatment (diarrhea). Therapy was discontinued after 3 – 10 months when thyroid eye disease had lead to fibrotic stage. This subgroup, with the exception of two women, who received corticosteroids additionally, presented stable disease. One of those had to be sent to surgery because of endangered optical nerve. Clinical ophthal­mological control showed promising results in patients receiving somatostatin analogues at early stage when positive on octreo-scan.</p>","PeriodicalId":6945,"journal":{"name":"Acta medica Austriaca","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1046/j.1563-2571.2001.01024.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72826043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Die ablative Therapie der Immunhyperthyreose unter spezieller Berücksichtigung der endokrinen Orbitopathie","authors":"P. Lind","doi":"10.1046/j.1563-2571.2001.01026.x","DOIUrl":"10.1046/j.1563-2571.2001.01026.x","url":null,"abstract":"<p><b>Zusammenfassung:</b> Der Einfluss einer ablativen Therapie einer immunogenen Hyperthyreose auf den Verlauf der endokrinen Orbitopathie wird weiterhin kontrovers diskutiert. Die vorliegende Datenlage ist sehr uneinheitlich, da es sich zum Teil um retrospektive Studien, zum Teil um prospektive Untersuchungen mit unterschiedlichen Nachbeobachtungszeiträumen und unterschiedlichen Patientenkollektiven handelt. Grundsätzlich scheint die Operation (near total resection) durch die weit­gehende Entfernung des thyreoidalen Antigens eher einen günstigen Einfluss auf den Verlauf der endokrinen Orbitopathie zu haben. Die meisten Untersuchungen belegen auch, dass die Radiojodtherapie die endokrine Orbitopathie ungünstig beeinflusst, da es in bis zu einem Drittel der Patienten zu einer Exazerbation oder zum Neuauftreten der endokrinen Orbitopathie kommt. Weitgehender Konsens besteht darüber, die Radiojodtherapie einer immunogenen Hyperthyreose unter Kortisonschutz durchzuführen. Die frühzeitige Gabe von L-Thyroxin nach Radiojodtherapie wirkt sich günstig auf die endokrine Orbitopathie aus, während eine zusätzliche Gabe von Methimazol keinen Einfuss zu haben scheint.</p><p>Ablative Therapy for Graves’ Hyperthyroidism in Patients with Ophthalmopathy</p><p><b>Summary:</b> The influence of ablative treatment of Graves’ disease on the course of endocrine ophthalmopathy is discussed controversially. Data are inhomogeneous, because some studies were performed retrospectively, some prospectively, because of different follow up periods and different patient groups. In principal near total resection seems to influence endocrine ophthalmpathy in a positive way, due to the removal of thyroid antigen. Most studies also demonstrate that treatment using radioiodine has a negative influence on ophthalmopathy, because the course of disease is worsening in up to one third of patients. There is also consensus that treatment of Graves’ disease with radioiodine should be performed only by concomitant administration of glucocor­ticoids. The early administration of L-thyroxine after radio­iodine therapy of Graves’ disease seems to have a positive influence on the course of disease, whereas additional treatment with methimazole has no positive influence on endocrine ophthalmopathy.</p>","PeriodicalId":6945,"journal":{"name":"Acta medica Austriaca","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1046/j.1563-2571.2001.01026.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78450791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Indikation und Technik der Orbitavergrößerung bei endokriner Orbitopathie","authors":"J. A. Obwegeser,&nbsp;B. Gattinger","doi":"10.1046/j.1563-2571.2001.01028.x","DOIUrl":"10.1046/j.1563-2571.2001.01028.x","url":null,"abstract":"<p><b>Zusammenfassung:</b> Die typischen Symptome der endokrinen Orbitopathie sind Folge der interstitiellen Verdickung der Augenmuskeln sowie der Volumenzunahme des retrobulbären Fett- und Bindegewebes. Das klinische Spektrum reicht von Lid- und Bindehautinfiltrationen, Exophthalmus, Muskelverdickungen und Doppelbildern, Hornhautschädigungen bis hin zur Seh­nervbeteiligung mit Visusabfall. Bei einer Funktionsstörung des Sehnerven stellt die chirurgische Orbitavergrößerung eine Ultima Ratio dar. Das chirurgische Prinzip beruht auf Dekompression im Bereich einer oder meist mehrerer Orbitawände, gelegentlich in Kombination mit einer sagittalen Vergrößerung der Orbita durch Osteotomie und Vorverlagerung der ventralen Orbitaabschnitte. Als Faustregel gilt: Die Reduktion des Exophthalmus ist proportional zur Anzahl der dekomprimierten Wände und beträgt 2 – 3 mm pro dekomprimierter Orbitawand. Durch Vorverlagerung des ventralen Orbitaringes kann eine darüber hinaus gehende Exopthalmusreduktion erzielt werden.</p><p>Indication and Technique of Orbital Enlarge­ment in the Treatment of Endocrine Ophthalmo­pathy</p><p><b>Summary:</b> Typical symptoms in endocrine ophthalmo­pathy are a result of an interstitial swelling of the ocular muscles and of the volume increase of the postbulbar fat and connective tissue. Clinically, we find a spectrum that reaches from infiltration of the eyelid and conjunctival tissue, exo­phthalmos, swelling of the muscles with diplopia, damage to the cornea till to involvement of the optic nerve with loss of vision. Regarding functional impairment of the optic nerve, orbital decompression represents an operative ultimate ratio. The surgical principle is based on the decompression within one or usually several orbital walls occasionally in combination with a sagittal enlargement of the eye socket by osteo­tomy and advancement of the orbital rims. As rule of thumb is considered: The reduction of the exophthalmos is pro­portional to the number of decompressed walls and amounts to 2 – 3 mm per decompressed orbital wall. A reduction of exophthalmos going beyond that can be obtained by advancement of the orbital rims.</p>","PeriodicalId":6945,"journal":{"name":"Acta medica Austriaca","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1046/j.1563-2571.2001.01028.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79296395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bestrahlungsbehandlung der endokrinen Orbitopathie – State of the Art","authors":"Ulrike Prettenhofer,&nbsp;Sigrid Ramschak-Schwarzer,&nbsp;Andrea Langmann,&nbsp;R. Mayer,&nbsp;P. Schedlbauer,&nbsp;A. Hackl","doi":"10.1046/j.1563-2571.2001.01023.x","DOIUrl":"10.1046/j.1563-2571.2001.01023.x","url":null,"abstract":"<p><b>Zusammenfassung:</b> Seit mehreren Jahrzehnten stellt die endokrine Orbitopathie entweder als alleinige Behandlungsform oder in Kombination mit einer Kortisontherapie eine Indikation für die Strahlentherapie dar. Damit kann bei zirka zwei Drittel der Patienten eine Besserung der entzündlichen Schwellung des orbitalen Bindegewebes und der eingeschränkten Augenmuskelbeweglichkeit erzielt werden.</p><p>Radiotherapy of Graves' Disease –State of the Art</p><p><b>Summary:</b> Since several decades, radiotherapy is included in the multimodal treatment concept of Graves' disease. By using orbital irradiation alone or in combination with oral corticosteroids up to two thirds of the patients respond to the treatment and achieve improvement of soft tissue signs and extraocular muscle impairment.</p>","PeriodicalId":6945,"journal":{"name":"Acta medica Austriaca","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1046/j.1563-2571.2001.01023.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91499247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endokrine Orbitopathie – Diagnostik","authors":"Andrea Langmann,&nbsp;S. Lindner","doi":"10.1046/j.1563-2571.2001.01020.x","DOIUrl":"10.1046/j.1563-2571.2001.01020.x","url":null,"abstract":"<p><b>Zusammenfassung:</b> Zur Klassifikation der endokrinen Orbitopathie wird in unterschiedlich modifizierter Form die Klassifika­tion nach <i>Werner</i> (1969), das sogenannte NOSPECS-Schema herangezogen, dessen Anwendung im Folgenden anhand der Symptomatik der Patienten dargestellt wird.</p><p>Endocrine Orbitopathy – Diagnosis</p><p><b>Summary:</b> Various modifications of classic Werner classification for endocrine orbitopathy are used. The application of this NOSPECS-scheme on the ocular and periocular changes in Graves’ disease is discussed.</p>","PeriodicalId":6945,"journal":{"name":"Acta medica Austriaca","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1046/j.1563-2571.2001.01020.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83424469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Konservative Therapie bei endokriner Orbitopathie: „State of the Art”","authors":"M. Weissel","doi":"10.1046/j.1563-2571.2001.01022.x","DOIUrl":"10.1046/j.1563-2571.2001.01022.x","url":null,"abstract":"<p><b>Zusammenfassung:</b> Die vorliegende Übersicht beschreibt die international anerkannten konservativen (vor allem medikamentösen) Maßnahmen bei endokriner Orbitopathie. Diese müssen sich dem Schweregrad der Erkrankung anpassen. Die Objektivierung desselben kann Schwierigkeiten machen, weshalb auf die Bedeutung von entsprechenden Erhebungssystemen, wie zum Beispiel dem Clinical Activity Score, eingegangen wird. Zunächst steht die Sicherstellung einer normalen Schilddrüsenfunktion im Vordergrund. Bei milden Verlaufsformen reichen zusätzliche supportive lokale Maßnahmen. Bei schweren Verlaufsformen ist Kortison in verschiedenen Dosierungen und Applikationsarten das erste Mittel der Wahl. Die Ansprechrate der per os-Therapie liegt international bei ca. 63 %, jene der intravenösen hochdosierten Bolustherapie bei ca. 77 %. Als Alternative bzw. zur Kombination steht das ebenfalls nebenwirkungsreiche Immunsuppressivum Cyclosporin zur Verfügung. Die Kombination mit Kortison scheint nach übereinstimmenden Berichten der Kortison-Monotherapie überlegen. Eine weitere Alternative mit hochdosiertem, intravenös verabreichten Immunglobulinen ist zwar nebenwirkungsärmer bei gleicher Erfolgsrate wie die per os-Kortisontherapie, birgt aber die Infektionsgefahr aller Plasmaderivate in sich und ist außerdem extrem teuer. Abschließend werden noch neuere Therapieversuche mit Immunmodulatoren wie Pentoxifyllin oder Methotrexat, welche bisher nur an wenigen Patienten mit schweren Verlaufsformen – da allerdings mit eindrucksvollem Erfolg – erprobt worden sind, vorgestellt.</p><p>Medical Treatment of Endocrine Ophtalmopathy: “State of the Art”</p><p><b>Summary: </b> This review describes the state of the art of the conservative therapeutical approach of thyroid associated eye disease. Radiotherapy, surgery and ablative therapy of thyroid ophtalmopathy are discussed elsewhere in this issue of Acta Med Austriaca. All forms of therapy have to be adjusted to the severeness of the eye disease. The assessment of the ­severeness of this ailment can be difficult. Therefore, the impact of scoring systems like the “Clinical Activity Score” is pointed out. Treatment of thyroid dysfunction is the widely accepted first therapeutic measure. Additional supportive ­local therapy is usually sufficient in patients with only mild activity of endocrine ophtalmopathy. Glucocorticoids applied via different routes in various dose regimens are the therapy of first choice in (moderately) severe forms of the disease. Reported response rates for the oral form of therapy are about 63 %, for the intravenously applied very high doses (given only in very severe forms of the disease) nearly 77 %. Cyclosporin has been shown to be more efficient in combination with oral glucocorticoids in patients with moderately severe eye disease than glucocorticoids alone. Patients need a close follow up since both drugs have considerable side effects. An alternative treatment with highdose intravenous immunoglobuli","PeriodicalId":6945,"journal":{"name":"Acta medica Austriaca","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1046/j.1563-2571.2001.01022.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86082306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neues Design-Konzept zur Verbesserung der medizinischen Anwendersoftware","authors":"P. Knoll,&nbsp;G. Krotla,&nbsp;S. Mirzaei,&nbsp;K. Koriska,&nbsp;H.-D. Köhn","doi":"10.1046/j.1563-2571.2003.03001.x","DOIUrl":"10.1046/j.1563-2571.2003.03001.x","url":null,"abstract":"","PeriodicalId":6945,"journal":{"name":"Acta medica Austriaca","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1046/j.1563-2571.2003.03001.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22390254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}